San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Ansun BioPharma is raising $67,088,386.00 in a new round of investment. Sources indicate as part of senior management Founder, Mang Yu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies.

To learn more about Ansun BioPharma, visit http://www.ansunbiopharma.com/

Contact:
Mang Yu, Founder
858-452-2631
myu@ansunbiopharma.com
https://www.linkedin.com/in/mangyu/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved